What is Emergent Biosolutions's D&A?

Emergent Biosolutions (EBS) reported D&A of $16.5M in Q1 2026.

How has Emergent Biosolutions's D&A changed year-over-year?

Emergent Biosolutions's D&A increased by 1.2% year-over-year, from $16.3M to $16.5M.

What is the long-term trend for Emergent Biosolutions's D&A?

Over 4 years (2021 to 2025), Emergent Biosolutions's D&A has grown at a 2.7% compound annual growth rate (CAGR), from $58.5M to $65.1M.

Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.

Emergent Biosolutions EBS D&A

D&A at other companies

CorMedixCRMD

$10.54M+20,197%

Opko HealthOPK

$18.97M-4.5%

Medline, Inc. MDLN

$254M+2.8%

Charles River LaboratoriesCRL

$67.15M-44.2%

Baxter InternationalBAX

$237M-4.0%

West Pharmaceutical ServicesWST

——

Segments

By segment

See full

MCM Products$4.6M+9.5%

All other segment$800K—

Other financials

Income statement

See full

Revenue$156.1M-29.7%

Gross profit$84.1M-37.1%

Operating income$10.5M-79.0%

Net income$6.8M-90.0%

EPS (diluted)$0.07-94.1%

Balance sheet

See full

Cash & equivalents$161.5M+5.7%

Total debt$584.6M-13.1%

Total equity$523.1M-5.4%

Total assets$1.3B-7.4%

Cash flow

See full

Operating cash flow-$33.8M-202%

CapEx$2.4M-33.3%

Free cash flow-$36.2M-145%

Valuation

See full

Market cap$411.74M+22.0%

Enterprise value$834.84M-2.6%

P/E3.6×—

P/S0.6×+0.3×

Profitability

See full

Gross margin54.2%+19.0pp

Operating margin15%+10.3pp

Net margin9.6%+5.8pp

FCF margin20.8%—

Returns & leverage

See full

Return on equity13.9%+8.1pp

Debt / equity1.1×-0.1×

Current ratio4.3×-2.0×

Where this comes from

Reported directly by Emergent Biosolutions in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.

The official record: Emergent Biosolutions’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Emergent Biosolutions's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Emergent Biosolutions's D&A?: Emergent Biosolutions (EBS) reported D&A of $16.5M in Q1 2026.
How has Emergent Biosolutions's D&A changed year-over-year?: Emergent Biosolutions's D&A increased by 1.2% year-over-year, from $16.3M to $16.5M.
What is the long-term trend for Emergent Biosolutions's D&A?: Over 4 years (2021 to 2025), Emergent Biosolutions's D&A has grown at a 2.7% compound annual growth rate (CAGR), from $58.5M to $65.1M.
What does D&A mean?: Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.